K. Na BangchangT. M.E. DavisS. LooareesuwanN. J. WhiteD. BunnagJ. KarbwangMahidol UniversityNuffield Department of Clinical Medicine2018-02-272018-02-271994-01-01Transactions of the Royal Society of Tropical Medicine and Hygiene. Vol.88, No.3 (1994), 321-323003592032-s2.0-0028229619https://repository.li.mahidol.ac.th/handle/123456789/9603Mefloquine has an established place in the treatment of chloroquine-resistant falciparum malaria. To investigate mefloquine pharmocokinetics in pregnancy, 9 untreated pregnant women aged 16-33 years and 8 non-pregnant females aged 16-38 years received an average of 15 (range 13-19) mg mefloquine/kg body-weight as single-dose treatment for uncomplicated falciparum malaria. Regular blood samples were taken during the subsequent 48 h and then intermittently for 3-26 d after treatment. Whole blood mefloquine concentrations were analysed by high-performance liquid chromatography and a one-compartment open pharmacokinetic model was fitted to the data. Peak mefloquine concentrations were significantly lower in the pregnant patients (median [range]; 1257 [650-1584] vs. 1617 [1051-3111] ng/mL) and the total apparent volume of distribution ( V d f) was larger (10·8 [8·3-26·1] vs. 10·0 [4·8-13·9] L/kg; P < 0·05 in each case), consistent with an expanded circulating blood volume and increased tissue binding in pregnancy. There was no significant difference between the 2 groups in half-times of absorption or elimination (P > 0·1), and systemic clearance rates were also similar. These results suggest that pregnant patients need larger doses of mefloquine than non-pregnant women to achieve comparable blood levels, an important consideration in areas where multi-drug resistant falciparum malaria is emerging. © 1994.Mahidol UniversityImmunology and MicrobiologyMedicineArticleSCOPUS10.1016/0035-9203(94)90101-5